Drug Approval | September 03, 2021
Covid-19 vaccine clinical trial for people with autoimmune disease
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
Key trends indicate that AI-based solutions, cloud-based healthcare solutions and digital transformations will be the key in the years to come.
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
The company has been sold to Shinshin Pharmaceuticals
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian market
This is the third acquisition by Healthium this year apart from AbGel business in India and VitalCare in the UK
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
